PE20081364A1 - Composicion farmaceutica que comprende valsartan - Google Patents

Composicion farmaceutica que comprende valsartan

Info

Publication number
PE20081364A1
PE20081364A1 PE2007001173A PE2007001173A PE20081364A1 PE 20081364 A1 PE20081364 A1 PE 20081364A1 PE 2007001173 A PE2007001173 A PE 2007001173A PE 2007001173 A PE2007001173 A PE 2007001173A PE 20081364 A1 PE20081364 A1 PE 20081364A1
Authority
PE
Peru
Prior art keywords
modifier
pharmaceutical composition
valsartan
composition including
acid
Prior art date
Application number
PE2007001173A
Other languages
English (en)
Inventor
Dieter Becker
Barbara Luckel
Stefanie Siepe
Jorg Ogorka
Bruno Galli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39047776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081364(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06120038A external-priority patent/EP1897537A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081364A1 publication Critical patent/PE20081364A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA, QUE COMPRENDE i) UN COMPUESTO DE FARMACO ACIDO TAL COMO UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II SIENDO PEREFERIDO VALSARTAN; ii) AL MENOS UN MODIFICADOR DE pH QUE TIENE UN pKa MAYOR DE 2 SIENDO SELECCIONADO DE ACIDO CITRICO, FUMARICO, SUCCINICO, ADIPICO Y MALEICO, DONDE LA PROPORCION PESO/PESO DEL MODIFICADOR DE pH AL FARMACO ACIDO ES ENTRE 0.01:1 Y 10:1; Y iii) AL MENOS UN EXCIPIENTE; ADEMAS COMPRENDE UN POLIMERO DE MATRIZ QUE COMPRENDE HIDROXI-PROPIL-CELULOSA QUE CONTIENE UNA DISPERSION SUSTANCIALMENTE UNIFORME DEL FARMACO ACIDO Y EL MODIFICADOR DE pH. ESTA COMPOSICION SE ADAPTA PARA PROPORCIONAR UN pH MICRO-AMBIENTAL DE 5 O MENOS EN CUANDO MENOS UNA REGION DEL TRACTO GASTRO INTESTINAL; SIENDO UTIL EN EL TRATAMIENTO DE HIPERTENSION, INSUFICIENCIA CARDIACA O INFARTO DE MIOCARDIO
PE2007001173A 2006-09-04 2007-08-29 Composicion farmaceutica que comprende valsartan PE20081364A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120038A EP1897537A1 (en) 2006-09-04 2006-09-04 Composition comprising an angiotensin II receptor antagonist
EP07103396 2007-03-02

Publications (1)

Publication Number Publication Date
PE20081364A1 true PE20081364A1 (es) 2008-12-04

Family

ID=39047776

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001173A PE20081364A1 (es) 2006-09-04 2007-08-29 Composicion farmaceutica que comprende valsartan

Country Status (5)

Country Link
AR (1) AR062613A1 (es)
CL (1) CL2007002553A1 (es)
PE (1) PE20081364A1 (es)
TW (1) TW200817054A (es)
WO (1) WO2008028885A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
US20140127299A1 (en) * 2012-11-07 2014-05-08 NaZura BioHealth, Inc. GRAS Enteric Coating Formulations and Methods of Making and Using Same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
WO1999044590A1 (en) * 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
EP1258254A4 (en) * 2000-02-21 2004-02-04 Takeda Chemical Industries Ltd COMPOSITIONS FOR DELAYED DELIVERY OF PHYSIOLOGICALLY ACTIVE COMPOUNDS THAT ARE LOW WATER-SOLUBLE, METHOD FOR THE PRODUCTION AND USE THEREOF
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
CA2592091A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan

Also Published As

Publication number Publication date
WO2008028885A2 (en) 2008-03-13
TW200817054A (en) 2008-04-16
WO2008028885A3 (en) 2008-05-02
CL2007002553A1 (es) 2008-05-16
AR062613A1 (es) 2008-11-19

Similar Documents

Publication Publication Date Title
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
CL2008003339A1 (es) Compuestos derivados de pirimidin-2(1h)-ona, inhibidores de la 11b-hidroxiesteroide deshidrogenasa 1; composicion farmaceutica, util para el tratamiento de enfermedades tales como obesidad, hipertension e hiperlipidemia.
PE20120428A1 (es) Composicion farmaceutica solida que comprende amlodipina y losartan
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
PE20090038A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y de farmacos
AR069554A1 (es) Compuesto triciclico de amino benzoimidazol
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
MY158299A (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
CO6382125A2 (es) Inhibidores de proteína quinasa
EA200970088A1 (ru) Модуляторы метаболизма и лечение связанных с ним нарушений
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
DE602005023124D1 (de) Spirobenzodioxole und deren verwendung als cb1-antagonisten
CY1105479T1 (el) Παραγωγα τετραζολιου και μεθοδοι αντιμετωπισης σχετιζομενων με τον μεταβολισμο διαταραχων με αυτα
AR066168A1 (es) Formulaciones galenicas de compuestos organicos
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
CR20110209A (es) Composición farmacéutica sólida
EA200800421A1 (ru) Соединения
EA201201662A1 (ru) Дизамещенные тетрагидрофуранильные соединения в качестве антагонистов брадикининового рецептора в1
CY1112702T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της
PE20110103A1 (es) Derivado de piperidinilo como modulador de la actividad de los receptores de quimiocinas
PE20081364A1 (es) Composicion farmaceutica que comprende valsartan
GEP20125526B (en) Drug active in neuropathic pain
WO2011080502A3 (en) New pharmaceutical dosage form for the treatment of gastric acid-related disorders

Legal Events

Date Code Title Description
FD Application declared void or lapsed